HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A CCR4 antagonist combined with vaccines induces antigen-specific CD8+ T cells and tumor immunity against self antigens.

Abstract
Regulatory T cells (Tregs) may impede cancer vaccine efficacy in hematologic malignancies and cancer. CCR4 antagonists, an emergent class of Treg inhibitor, have been shown to block recruitment of Tregs mediated by CCL22 and CCL17. Our aim was to demonstrate the ability of a CCR4 antagonist (a small chemical molecule identified in silico) when combined with vaccines to break peripheral tolerance controlled by Tregs, a prerequisite for the induction of CD8(+) T cells against self Ags. Immunization of transgenic or normal mice expressing tumor-associated self Ags (Her2/neu, OVA, gp100) with a CCR4 antagonist combined with various vaccines led to the induction of effector CD8(+) T cells and partial inhibition of tumor growth expressing self Ags in both prophylactic and therapeutic settings. The CCR4 antagonist was more efficient than cyclophosphamide to elicit anti-self CD8(+) T cells. We also showed that the population of Tregs expressing CCR4 corresponded to memory (CD44(high)) and activated (ICOS(+)) Tregs, an important population to be targeted to modulate Treg activity. CCR4 antagonist represents a competitive class of Treg inhibitor able to induce functional anti-self CD8(+) T cells and tumor growth inhibition when combined with vaccines. High expression of CCR4 on human Tregs also supports the clinical development of this strategy.
AuthorsHelene Pere, Yves Montier, Jagadeesh Bayry, Francoise Quintin-Colonna, Nathalie Merillon, Estelle Dransart, Cecile Badoual, Alain Gey, Patrice Ravel, Elie Marcheteau, Frederic Batteux, Federico Sandoval, Olivier Adotevi, Christopher Chiu, Sylvie Garcia, Corinne Tanchot, Yu-Chun Lone, Luis Carlos Ferreira, Brad H Nelson, Douglas Hanahan, Wolf Herman Fridman, Ludger Johannes, Eric Tartour
JournalBlood (Blood) Vol. 118 Issue 18 Pg. 4853-62 (Nov 03 2011) ISSN: 1528-0020 [Electronic] United States
PMID21908423 (Publication Type: Evaluation Study, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antigens, Neoplasm
  • Antineoplastic Agents
  • Autoantigens
  • Cancer Vaccines
  • Ccr4 protein, mouse
  • Immunologic Factors
  • Receptors, CCR4
Topics
  • Animals
  • Antigens, Neoplasm (immunology)
  • Antineoplastic Agents (administration & dosage)
  • Autoantigens (drug effects, immunology)
  • CD8-Positive T-Lymphocytes (drug effects, immunology)
  • Cancer Vaccines (administration & dosage)
  • Combined Modality Therapy
  • Disease Models, Animal
  • Female
  • Humans
  • Immunologic Factors (administration & dosage)
  • Mice
  • Mice, Inbred C57BL
  • Mice, Transgenic
  • Neoplasms (genetics, immunology, pathology, therapy)
  • Receptors, CCR4 (antagonists & inhibitors)
  • T-Cell Antigen Receptor Specificity (drug effects, immunology)
  • Tumor Escape (drug effects, immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: